Fulvestrant With or Without AZD6244, a Mitogen-Activated Protein Kinase Kinase (MEK) 1/2 Inhibitor, in Advanced Stage Breast Cancer Progressing After Aromatase Inhibitor: A Randomized Placebo-Controlled Double-Blind Phase II Trial.

Trial Profile

Fulvestrant With or Without AZD6244, a Mitogen-Activated Protein Kinase Kinase (MEK) 1/2 Inhibitor, in Advanced Stage Breast Cancer Progressing After Aromatase Inhibitor: A Randomized Placebo-Controlled Double-Blind Phase II Trial.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Fulvestrant (Primary) ; Selumetinib
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 14 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2020.
    • 14 Dec 2013 Primary endpoint 'Disease-control-rate' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top